title: Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
abstract: The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.
authors.affiliation: Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA. adesai@medicine.bsd.uchicago.edu
authors.forename: Apurva A
authors.initials: AA
authors.lastname: Desai
authors.forename: Walter M
authors.initials: WM
authors.lastname: Stadler
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D004791:Enzyme Inhibitors; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D066246:ErbB Receptors; D000077210:Sunitinib
references.citation: Nature. 1999 May 20;399(6733):271-5
references.pmid: 10353251
references.citation: Clin Cancer Res. 2004 Sep 15;10 (18 Pt 2):6290S-5S
references.pmid: 15448019
references.citation: J Clin Oncol. 2005 Sep 1;23(25):5892-9
references.pmid: 16043829
references.citation: J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
references.pmid: 10655437
references.citation: Cancer Res. 2000 Dec 15;60(24):7075-83
references.pmid: 11156414
references.citation: Lancet. 1998 Nov 21;352(9141):1691-6
references.pmid: 9853456
references.citation: Ann Surg Oncol. 2004 Jan;11(1):71-7
references.pmid: 14699037
references.citation: J Urol. 2003 Oct;170(4 Pt 1):1141-5
references.pmid: 14501711
references.citation: Invest New Drugs. 2003 Aug;21(3):341-5
references.pmid: 14578682
references.citation: N Engl J Med. 2004 Jun 3;350(23 ):2335-42
references.pmid: 15175435
references.citation: CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
references.pmid: 14974761
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9
references.pmid: 8855223
references.citation: Am J Nephrol. 2004 Jan-Feb;24(1):1-13
references.pmid: 14654728
references.citation: J Clin Oncol. 2002 Nov 15;20(22):4478-84
references.pmid: 12431972
references.citation: Cancer Res. 1998 Feb 15;58(4):808-14
references.pmid: 9485039
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: J Nucl Med. 2004 Jan;45(1):17-21
references.pmid: 14734662
references.citation: Nat Genet. 1994 May;7(1):85-90
references.pmid: 7915601
references.citation: Oncogene. 2003 Jul 31;22(31):4918-23
references.pmid: 12894235
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4
references.pmid: 7937876
references.citation: Biochim Biophys Acta. 1996 Mar 18;1242(3):201-10
references.pmid: 8603073
references.citation: Clin Cancer Res. 2004 Apr 15;10 (8):2584-6
references.pmid: 15102658
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: J Clin Oncol. 2001 Feb 1;19(3):843-50
references.pmid: 11157038
references.citation: Invest New Drugs. 2003 Feb;21(1):99-101
references.pmid: 12795534
references.citation: Pharmacol Ther. 2004 Apr;102(1):37-46
references.pmid: 15056497
references.citation: Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8
references.pmid: 12522270
references.citation: N Engl J Med. 2003 Jul 31;349(5):427-34
references.pmid: 12890841
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: Cochrane Database Syst Rev. 2000;(3):CD001425
references.pmid: 10908496
references.citation: Oncologist. 2004;9(3):271-81
references.pmid: 15169982
references.citation: J Urol. 2000 Feb;163(2):408-17
references.pmid: 10647643
references.citation: Cancer Res. 2002 May 15;62(10 ):2957-61
references.pmid: 12019178
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Semin Oncol. 2000 Apr;27(2):124-37
references.pmid: 10768592
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3955-64
references.pmid: 14517187
references.citation: Cancer. 1994 Apr 1;73(7):1913-8
references.pmid: 8137218
references.citation: Cancer. 2003 Oct 15;98(8):1611-9
references.pmid: 14534876
references.citation: Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
references.pmid: 7612182
references.citation: Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1
references.pmid: 12503822
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Biochem Biophys Res Commun. 2004 Apr 30;317(2):358-62
references.pmid: 15063765
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3127-32
references.pmid: 12915604